For Healthcare Professionals

A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

clipboard-pencil

About the study

The purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria

  1. Subjects must be at least 18 years of age on day of signing informed consent, regardless of gender;
  2. Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC ;
  3. Subjects for NSCLC should be confirmed to be EGFR (Epidermal growth factor receptor) wild-type and ALK (Anaplastic lymphoma kinase) fusion gene negative; or confirmed to harbor EGFR mutation;
  4. Locally advanced or metastatic NSCLC subjects without actionable EGFR mutations and ALK fusion genes, no prior systemic treatment; subjects with EGFR mutation, no prior systemic treatment or failed prior EGFR-TKI (Tyrosine kinase inhibitor) treatment;
  5. Subjects are able to provide tumor blocks or slides before the first dose of study intervention;
  6. Subject must have at least one radiographically measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria;
  7. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1;
  8. Life expectancy at least 3 months for the subject;
  9. Adequate organ function;
  10. Subjects must have recovered from all toxicities led by prior treatment;
  11. Contraceptive methods used by male and female subjects must comply with contraceptive methods of local regulations for clinical study subjects;
  12. Subjects should voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures.

EXCLUSION CRITERIA

Exclusion Criteria

  1. Subjects with mixed SCLC histopathological features;
  2. Subjects with a known history of prior malignancy;
  3. Subjects with known meningeal metastases, brainstem metastases, spinal cord metastases and/or compression, or active central nervous system (CNS) metastases;
  4. Subjects with ≥ Grade 2 peripheral neuropathy;
  5. Subjects who had arteriovenous thromboembolic events;
  6. Subjects with active inflammatory bowel disease or previous clear history of inflammatory bowel disease;
  7. Subjects who suffer from cardiovascular diseases of clinical significance;
  8. Subjects with a history of interstitial lung disease (ILD)/non-infectious pneumonitis that required steroids;
  9. Subjects with uncontrolled systemic disease as judged by the Investigator;
  10. Subjects with active autoimmune disease that required systemic treatment in the past 2 years;
  11. Subjects with active hepatitis B or hepatitis C;
  12. Subjects with known history of Human Immunodeficiency Virus (HIV)
  13. Subjects with known active tuberculosis;
  14. Subjects with known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
  15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study;
  16. Subjects whose condition deteriorated rapidly, such as severe changes in performance status, during the screening process prior to the first dose of study intervention;
  17. Subjects with other circumstances that, in the opinion of the Investigator, are not appropriate for participation in this study.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 86-028-67255165Email iconEmail Study Center

Study Details


Contition

Non-small Cell Lung Cancer

Age

18+

Phase

PHASE2

Participants Needed

278

Est. Completion Date

Aug 31, 2026

Treatment Type

INTERVENTIONAL


Sponsor

Klus Pharma Inc.

ClinicalTrials.gov NCT Identifier

NCT05816252

Study Number

SKB264-II-04

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.